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Abstract
Cervical cancer is the second leading cause of cancer death among women in developing countries. Developing countries
often lack infrastructure, cytotechnologists, and pathologists necessary to implement current screening tools. Due to their
low cost and ease of interpretation at the point-of-care, optical imaging technologies may serve as an appropriate solution
for cervical cancer screening in low resource settings. We have developed a high-resolution optical imaging system, the
High Resolution Microendoscope (HRME), which can be used to interrogate clinically suspicious areas with subcellular
spatial resolution, revealing changes in nuclear to cytoplasmic area ratio. In this pilot study carried out at the women’s clinic
of Princess Marina Hospital in Botswana, 52 unique sites were imaged in 26 patients, and the results were compared to
histopathology as a reference standard. Quantitative high resolution imaging achieved a sensitivity and specificity of 86%
and 87%, respectively, in differentiating neoplastic ($CIN 2) tissue from non-neoplastic tissue. These results suggest the
potential promise of HRME to assist in the detection of cervical neoplasia in low-resource settings.
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Introduction
Cervical cancer is the third most common type of cancer among
women worldwide. In 2008, there were an estimated 530,000 new
cases and more than 275,000 deaths due to cervical cancer. Over
85% of new cases of cervical cancer and deaths due to cervical
cancer occur in developing countries where screening programs
for early detection are either inadequate or unavailable [1].
In the United States and many other high-resource countries,
organized screening programs based on the Pap (Papanicolaou)
smear and human papillomavirus (HPV) tests enable early
diagnosis and treatment of precancerous lesions. An abnormal
Pap smear test or HPV test is followed by colposcopy. If
abnormalities are evident under colposcopy, a biopsy is required
to confirm disease before treatment. The widespread use of Pap
smears, colposcopy, biopsy, and treatment of pre-cancerous lesions
has led to dramatic reductions in the incidence and mortality of
cervical cancer in the United States [2]. However, this process
requires multiple patient visits and highly trained personnel to
read cytology and biopsy results. In resource-constrained settings,
the increased risk of patient loss to follow-up and lack of trained
personnel and laboratories often make this screening paradigm
ineffective.
HPV testing has been explored in developing countries and the
available data have demonstrated the potential of HPV testing to
reduce both the mortality and long term risk of cervical cancer [3].
However, currently available HPV tests require six hours to
produce a result, necessitating multiple visits for screening and
treatment. More recently, rapid HPV tests have emerged which
may offer a potential solution, but are yet to become commercially
available [4].
Alternative early cervical cancer detection methods that are
accurate, low cost, and that allow immediate diagnosis and
treatment in a single visit are crucial for low-resource countries [5].
Visual inspection with acetic acid (VIA) is the most widely
available screening modality in developing countries. This is a
simple visual test, in which the cervix is examined with the naked
eye before and after application of 3 to 5% acetic acid (vinegar).
Upon application of the acetic acid, suspicious areas turn white.
VIA has been explored in various developing countries as an
alternative to cytology, and has shown promising results in
detecting high-grade dysplasia or invasive carcinomas [6,7].
Although not as extensively used as VIA, visual inspection with
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Lugol’s iodine (VILI) has shown promising results compared to
both Pap smear and VIA. In a multicenter study in several
developing countries involving 56,939 women, the sensitivity of
VIA varied from 67-79% and specificity ranged from 49%-86%,
while the sensitivity and specificity of VILI varied from 76%–97%
and 73%–92%, respectively [6]. VIA and VILI are inexpensive,
require minimal infrastructure, allow for immediate treatment,
and eliminate the need for a laboratory. Despite the advantages of
VIA and VILI over cytology, these tests are subjective, requiring
extensive and ongoing training of health-care providers, and are
frequently associated with low specificity, which can result in
significant overtreatment.
As an alternative to visual examination of the cervix, high
resolution fiber optic microscopes are now available which
facilitate direct visualization of neoplastic indicators such as
elevated nuclear to cytoplasmic area ratio, nuclear crowding,
and pleomorphic nuclei. These indicators are conventionally only
observed during cytologic or histologic analysis following an
invasive biopsy. Vital dyes can provide high optical contrast if
applied topically. For example, proflavine, a fluorescent DNA
label, distinguishes nuclei from the cytoplasm of the cell with
nuclei appearing bright. Proflavine has peak absorbance at
445 nm and a peak emission at 510 nm. High-resolution
fluorescence imaging of this agent in tissue can yield morphologic
information such as the nuclear-to-cytoplasmic ratio which is an
important parameter used in the histological diagnosis of cancer. It
has a long history of safe clinical use as a topical antiseptic [8,9],
and is a component of acriflavine, which has been used in clinical
imaging studies of the gastrointestinal tract and cervix [10,11].
Due to their low cost and ease of interpretation at the point-of-
care, high resolution optical imaging technologies may serve as an
appropriate solution for cervical cancer screening in low resource
settings [12]. We recently developed a high resolution microendo-
scope (HRME) to address the limitations of conventional methods
of cervical cancer screening. The HRME has been evaluated in
pilot studies of oral and esophageal precancer diagnosis [13–15].
In these studies, proflavine is applied topically to the squamous
epithelium, and the area is interrogated with a fiber-optic bundle.
Changes in cell morphology and epithelial architecture can be
visualized in real time on a laptop computer.
The objective of this study was to evaluate the ability of this
high-resolution microendoscope to identify cervical neoplasia in
patients at the women’s clinic at Princess Marina Hospital in
Botswana. Images were acquired from 52 sites in 26 patients. The
images acquired by the microendoscope were assessed by both
visual inspection by two expert observers and quantitative analysis
to discriminate neoplastic ($CIN 2) from non-neoplastic cervical
tissue. Results were compared to histopathology as the reference
standard.
Materials and Methods
Instrumentation
Images were acquired using a custom designed, low cost high-
resolution microendoscope (HRME); this system has been
described in detail previously [16]. Briefly, the HRME is a fiber-
optic fluorescence microscope which can acquire images of tissue
with sub-cellular resolution at video-rate. As shown in Fig. 1, the
HRME consists of a coherent, flexible 1 mm diameter fiber
bundle (Sumitomo, IGN-08/30) coupled to a light source and a
digital CCD camera. Light from a blue LED with peak
wavelength centered at 455 nm (Thorlabs, FB450-40) provides
illumination; fluorescence emission from the tissue is collected by
the bundle, transmitted through a 475 nm dichroic mirror
(Chroma, 475DCXRU), and focused onto an optical sensor of
the CCD camera (Point Grey Research, GRAS-14S5C-M) by an
objective lens (106/0.25) and a 150 mm tube lens. Images are
transferred to a laptop via IEEE-1394 (Firewire) cable. The field of
view of the HRME is 720 mm in diameter, and the lateral spatial
resolution is approximately 4 mm.
Clinical Measurements
Women attending a colposcopy clinic on the basis of an
abnormal Pap smear were eligible to participate in the study if they
were at least 18 years of age and not pregnant. A health care
provider described the procedure to eligible patients; patients who
agreed to participate were provided with and signed forms
indicating informed consent and authorization.
Study participation included colposcopic examination of the
vulva, vagina, and cervix using 3% acetic acid. Abnormal cervical
lesions in the transformation zone were identified and noted by the
study physician, in accordance with routine patient care. Each
lesion was described and classified by the study physician as
clinically high grade, clinically low grade, or clinically normal
using the Reid Colposcopic Index [17]. Following routine
colposcopic examination, a solution of proflavine hemisulfate
(0.01% w/v in sterile phosphate buffered saline) was topically
applied to the cervix with a cotton swab. Following application of
proflavine, the HRME was advanced through the speculum and
placed in gentle contact with the cervix. Three second movies were
obtained by the HRME from up to two clinically abnormal
cervical sites and one clinically normal cervical site in the
Figure 1. Photograph of the high resolution micro-endoscope
(HRME).
doi:10.1371/journal.pone.0044924.g001
A Pilot Study
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transformation zone. Following optical measurements, all sites
interrogated with the HRME probe were biopsied and submitted
for routine histopathologic analysis. Biopsies were read by a single
pathologist who was blinded to the results of the optical imaging.
Diagnostic classification categories included normal, inflamma-
tion, HPV effect, grade 1 cervical intraepithelial neoplasia (CIN 1),
grade 2 cervical intraepithelial neoplasia (CIN 2), and grade 3
cervical intraepithelial neoplasia (CIN 3) using standard histo-
pathologic criteria [18]. Squamous metaplasia was considered a
normal result. No cases of carcinoma in situ (CIS) or squamous cell
carcinoma (SCC) were observed in this study. Low grade dysplasia
includes HPV effect and CIN 1, and high grade dysplasia includes
CIN 2 and CIN 3. Normal/benign results included inflammation.
For purposes of data analysis, neoplastic tissue was classified as
high grade dysplasia, and all other diagnoses were considered to be
non-neoplastic.
Data Analysis
For each HRME movie, one representative frame was chosen
which minimalized motion artifact and obstruction of the field of
view due to cellular debris. The user selecting the frames was
blinded to all diagnostic information. The resultant HRME images
were reviewed for quality control by a reviewer blinded to all
diagnostic information. Images were discarded if more than 50%
of the field of view was out of focus, contained evidence of motion
artifact, or contained significant debris. HRME images which
passed quality control and had a corresponding histopathologic
diagnosis were analyzed in two ways.
First, images were reviewed by two expert observers, who had
each previously reviewed HRME images from more than 50 cases
of normal and neoplastic tissues. HRME images passing quality
control were presented to each reviewer in randomized order;
reviewers were instructed to classify each image as non-neoplastic
or neoplastic. The sensitivity and specificity of qualitative analysis
Figure 2. Comparison of colposcopic appearance, HRME images, and histologic diagnosis. The top row shows images obtained from a
clinically normal region of the cervix. The white arrow in the colposcopic image (a) indicates the area imaged with the HRME. The HRME image (b)
shows small, uniformly spaced nuclei, and was considered non-neoplastic by both subjective expert observers, which is consistent with
histopathology indicating HPV effect (c). The bottom row shows images from a clinically abnormal region of the cervix. The white arrow in the
colposcopic image (d) indicates a region with a clinical impression of high grade disease. The corresponding HRME image (e) shows large,
pleomorphic, crowded nuclei and was considered neoplastic by both subjective expert observers, which is consistent with histopathology indicating
CIN3 (f).
doi:10.1371/journal.pone.0044924.g002
Table 1. Number of sites imaged by HRME, grouped according to histopathology diagnosis.
Diagnostic Category Histopathology Diagnosis Number of Sites Imaged
Normal/Benign Normal 5
Inflammation 7
Low Grade Dysplasia HPV Effect 11
CIN I 7
High Grade Dysplasia CIN 2 2
CIN 3 12
Total Number of Sites Imaged 44
High grade dysplasia was considered neoplastic.
All other categories were considered non-neoplastic.
doi:10.1371/journal.pone.0044924.t001
A Pilot Study
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was calculated for each reviewer using histopathologic diagnosis as
the reference standard.
Second, image analysis software was used to analyze each
HRME image which passed quality control to calculate quanti-
tative image features. Analysis focused on assessment of nuclear
size, since changes in nuclear size and nuclear-to-cytoplasmic ratio
are hallmark histopathologic features of cervical precancer [19]. A
reviewer, blinded to the histopathologic diagnosis, first manually
selected a region of interest (ROI) for quantitative analysis. The
ROI was selected to include regions with visible nuclei and to
exclude regions with evidence of motion artifact, image saturation,
or debris. Following selection of the ROI from an HRME image,
image contrast was adjusted using a contrast-limited adaptive
histogram equalization, and median filtering was applied to
remove the background pattern associated with the structure of
the fiber bundle. Each processed gray-scale image was then
converted to a binary image using a threshold value. A reviewer,
again blinded to the histopathologic diagnosis, reviewed the binary
images and adjusted the threshold value to ensure that nuclei were
segmented appropriately based on visual assessment. Binary
images were then processed to remove all objects with fewer than
50 pixels (assumed to be noise) and more than 1500 pixels
(assumed to be debris). Finally, for each image the mean nuclear
to cytoplasmic area (N/C) ratio was calculated by dividing the
total nuclear area by the total cytoplasmic area within the ROI.
Ethics Statement
The study protocol was reviewed and approved by the
Institutional Review Board at Rice University and the Health
Research Division Office of the Botswana Ministry of Health.
Written informed consent documents were available in both
English and the local national language (Setswana). All patients
involved in the study gave written informed consent.
Results
HRME images were acquired from 52 sites in 26 patients.
Images from 8 sites were excluded from further analysis because
they did not pass quality control criteria outlined above. The
rejection of the 8 sites eliminated all data from one subject. For this
subject, the two movies collected were both out of focus because
the distal tip of the probe was not in contact with the cervical
epithelium. Table 1 summarizes the histopathologic diagnoses of
the remaining 44 sites. The majority of patients in the study were
human immunodeficiency virus (HIV) infected, which has been
correlated with a high incidence of intraepithelial lesions [20].
Figure 2 shows typical HRME images of clinically and
histopathologically normal (a–c) and neoplastic (d–f) cervical
tissues. The top row shows a colposcopic photograph of the cervix;
the white arrow indicates the clinically normal site where the
HRME probe was placed. The corresponding HRME image
shows small, regularly spaced nuclei. This image was considered
qualitatively non-neoplastic by both expert reviewers, which was
consistent with the histopathologic diagnosis of HPV effect. The
bottom row shows a colposcopic photograph indicating a clinically
abnormal thick aceto-white lesion (white arrow). The HRME
image obtained from this site shows large, crowded, pleomorphic
nuclei. The image was considered qualitatively neoplastic by both
expert observers, which was consistent with the histopathologic
diagnosis of CIN 3.
Figure 3 shows HRME images obtained from a case in which
the colposcopic impression did not agree with the histopathologic
diagnosis. The colposcopic photograph shows a warty lesion (white
arrow) which was classified as clinically high grade disease
according to the Reid Colposcopic Index. The HRME image
obtained from this site showed small nuclei, characteristic of
normal epithelium. The expert reviewers categorized this image as
non-neoplastic. This was consistent with the histopathologic
diagnosis of HPV effect.
Figure 3. Comparison of colposcopic appearance, HRME images, and histologic diagnosis in a case where colposcopic impression
did not agree with histopathologic diagnosis. The white arrow in the colposcopic image (a) indicates the area imaged with the HRME; the
clinical impression of this warty looking lesion was high grade disease according to the Reid Colposcopic Index. The HRME image (b) shows small,
uniformly spaced nuclei. This image was considered qualitatively non-neoplastic by both subjective expert observers, which is consistent with the
histologic image indicating HPV effect (c).
doi:10.1371/journal.pone.0044924.g003
Figure 4. HRME images were analyzed to calculate the average
nuclear to cytoplasmic (N/C) area ratio. A region of interest (green)
was defined by the user to select regions of the image with visually
observable nuclei. Within this region, a computer program segmented
nuclei and calculated the N/C area ratio. Representative images
showing a site diagnosed as HPV with an N/C ratio of 0.08 (a) and
site diagnosed as CIN 3 with an N/C ratio of 0.22 (b) are shown.
doi:10.1371/journal.pone.0044924.g004
A Pilot Study
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Qualitative diagnoses by the expert HRME observers for all 44
sites were compared with histopathologic diagnosis to calculate
sensitivity and specificity. Observer #1 classified the images with a
sensitivity and specificity of 86% and 70% respectively. Observer
#2 classified the images with a sensitivity and specificity of 93%
and 73% respectively.
Quantitative morphometric image analysis was next performed;
Figure 4 illustrates results from representative HRME images of
non-neoplastic and neoplastic tissues. In each image, the user-
defined ROI is outlined in green; within this ROI, the
automatically segmented nuclei are outlined in red. ROI size did
not vary significantly from neoplastic images to non-neoplastic
images (Student’s t-test, p.0.5). Figure 4a shows an HRME
image from a site histopathologically diagnosed as HPV effect; the
N/C ratio was 0.08. In contrast, Fig. 4b shows an HRME image
from a site diagnosed as CIN 3 with an N/C ratio of 0.22.
To assess whether differences in the N/C ratio as measured
from HRME images correlated with histopathologic diagnosis, we
grouped sites by histopathologic diagnosis and calculated the mean
of the N/C ratio (Fig. 5). Results show that the average N/C ratio
increases with increasing grade of neoplasia; the mean N/C ratio
of sites diagnosed as high grade dysplasia was significantly higher
than those diagnosed as normal/benign (Student’s t-test,
p = 2.061025) and those diagnosed as low grade (Student’s t-test,
p = 1.961025).
Figure 6 shows a scatter plot indicating the N/C ratio vs.
histopathologic diagnosis for each of the 44 sites measured in this
study. We explored whether this parameter could be used to
classify sites as neoplastic (high grade dysplasia) or non-neoplastic
(normal/benign or low grade dysplasia). Using a simple cut-off
where sites with an N/C ratio greater than 0.163 were diagnosed
as neoplastic and sites with an N/C ratio of less than 0.163 were
classified as non-neoplastic correctly classified 12 of 14 sites with a
histopathologic diagnosis of high grade, 16 of 18 sites with a
histopathologic diagnosis of low grade, and 10 of 12 sites with a
histopathologic diagnosis of normal/benign.
The receiver operator characteristic (ROC) curve for a
diagnostic algorithm based on the N/C ratio is shown in Fig. 7.
The Q-point indicated on the figure corresponds to the cut-off
value shown in Fig. 6, and corresponds to a sensitivity of 86% and
a specificity of 87%. Figure 7 also shows the accuracy of visual
interpretation of the HRME images by two observers relative to
the reference standard of histopathology. For both observers, the
accuracy of visual image interpretation lies near the ROC curve
for quantitative image interpretation. For comparison, the
sensitivity and specificity of clinical colposcopic impression for
the same sites were 64% and 83%, respectively when clinically low
grade lesions were considered non-neoplastic.
Discussion
This study suggests that high resolution microendoscopy shows
promise to improve cervical cancer screening in resource-
constrained settings. In this pilot study, both the sensitivity and
specificity of HRME based detection were higher than that of
colposcopic impression.
Figure 6. Scatter plot of N/C ratio for all samples, broken down
by histopathologic diagnosis. The dotted line indicates a threshold
at 0.163 with a sensitivity of 86% and a specificity of 87% for separating
samples diagnosed as high grade dysplasia from samples diagnosed as
low grade dysplasia or normal/benign.
doi:10.1371/journal.pone.0044924.g006
Figure 7. Receiver operator characteristic curve for the
algorithm shown in Figure 6. The star indicates the Q-point, with
a sensitivity of 86% and a specificity of 87%. The performance of visual
interpretation of HRME images by two observers is indicated and falls
along the ROC curve for automated image analysis. For comparison, the
sensitivity and specificity of clinical colposcopic impression for the same
sites were 64% and 83%, respectively.
doi:10.1371/journal.pone.0044924.g007
Figure 5. The average N/C ratio versus histopathologic
diagnosis by diagnostic category. The average N/C ratio of sites
diagnosed as high grade dysplasia was significantly higher than those
diagnosed as normal/benign (Student’s t-test, p = 2.0E-5) and low grade
dysplasia (Student’s t-test, p = 1.9E-5). Error bars indicate standard error.
doi:10.1371/journal.pone.0044924.g005
A Pilot Study
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While encouraging, our study has a number of limitations. First,
it was a pilot study involving only 52 sites in 26 patients. A larger,
prospective study is required to confirm the results. Second, all
HRME images were acquired from colposcopically suspicious and
normal areas in the transformation zone. We have not character-
ized HRME images of endocervical tissue to determine whether
they may be a potential source of error. Although all data in this
study was taken from the transformation zone of the cervix as
identified by the physician, three biopsies were noted to contain
predominantly columnar epithelium by pathology. Further
research is necessary to identify the differences between HRME
images of dysplastic squamous epithelium, normal columnar
epithelium, and dysplastic columnar epithelium.
High resolution imaging offers a number of potential advan-
tages as a screening tool. Studies of VIA have shown a wide range
of resulting sensitivities and specificities. A metastudy of VIA,
which included Sankaranarayanan’s multicenter study, revealed
sensitivities ranging from 41%–92% and specificities ranging from
49%–98% [21]. This significant variation in accuracy calls for
additional measures to maintain consistency of diagnoses. The
HRME system could potentially act as additional test to VIA and
VILI screening systems.
When VIA and VILI screening systems refer patients for
additional treatment, providers in low resource settings can choose
to screen and provide care in one visit. The ‘‘see and treat’’ system
eliminates biopsies to confirm disease in visible lesions before a
loop electrosurgical excision procedure (LEEP) or cautery [22].
Our results suggest that the HRME shows promise as a reliable
alternative to a biopsy at this second line of care in resource-
constrained areas. In particular, the high specificity of the HRME
results indicates that high resolution microendoscopy could
potentially lower the number of overtreated lesions.
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